Nautilus Reports Promising Q3 2025 with Key External Validation

Nautilus Biotechnology announced its Q3 2025 results, highlighting significant progress in validating its single-molecule proteomics platform. This includes a successful evaluation unit setup at the Buck Institute. The collaboration produced data on Tau proteoforms, confirming the reproducibility and revolutionary potential of Nautilus' technology for human health and longevity. These advancements, showcased at the HUPO 2025 conference, bolster Nautilus' credibility in the biotech market, potentially boosting investor confidence and supporting its NASDAQ stock momentum.